Uromigos-Bladder Cancer

Matthew D. Galsky, MDThe Uromigos | September 7, 2023
Matt Galsky continues his discussion on ctDNA in bladder cancer and covers topics such as candidate versus panel approaches.
Listen Now
The UromigosThe Uromigos | August 29, 2023
Dr. James Catto joins the podcast to compare robotic cystectomy against open cystectomy for patients with bladder cancer.
The UromigosThe Uromigos | August 16, 2023
Ananya Choudhury explains trimodality therapy for bladder cancer and myths around trimodal therapy and radical cystectomy.
The UromigosThe Uromigos | August 1, 2023
Matt Galsky, MD, talks about his new ctDNA study as well as how ctDNA may play a role in upcoming neoadjuvant trials.
The UromigosThe Uromigos | July 17, 2023
Yohann Loriot, MD, PhD, discusses the practice-changing THOR study data on the benefit of erdafitinib for advanced UC.
The UromigosThe Uromigos | June 6, 2023
Shilpa Gupta, MD discusses two oral abstracts from ASCO 2023 on the CONTACT-03 trial and the EV-103 trial.
The UromigosThe Uromigos | May 16, 2023
Dr. Meeks discusses expression-based subtypes for defining pathologic response to neoadjuvant ICIs in patients with MIBC.
The UromigosThe Uromigos | March 28, 2023
Sia Daneshmand, MD, reviews 2 studies on the use of erdafitinib for the treatment of NMIBC, including the THOR-2 trial.
The UromigosThe Uromigos | March 22, 2023
The Uromigos are joined by Kala Sridhar, MD, to discuss the PET MUSE study on the impact of PET imaging in MIUC.
The UromigosThe Uromigos | March 7, 2023
Michiel Van der Heijden, MD, PhD, joined The Uromigos to review bladder cancer research from the 2023 ASCO GU Symposium.
The UromigosThe Uromigos | February 21, 2023
Matt Galsky, MD discusses updates for the CheckMate 274 Trial at the 2023 ASCO GU Cancers Symposium with The Uromigos.
The UromigosThe Uromigos | February 18, 2023
Enrique Grande, MD, PhD, Msc, met with The Uromigos at the 2023 ASCO GU Cancers Symposium to discuss the IMvigor130 study.
The UromigosThe Uromigos | February 18, 2023
Andrea Necchi, MD describes the results of the phase 2 KEYNOTE-057 study at the 2023 ASCO GU Cancers Symposium.
The UromigosThe Uromigos | February 6, 2023
Vadim Koshkin, MD, discusses the prevalence of HER2 expression in bladder cancer and the UNITE study for advanced UC.
The UromigosThe Uromigos | January 31, 2023
Petros Grivas, MD, PhD, joins The Uromigos to discuss the use of antibody drug conjugates in bladder cancer.
The UromigosThe Uromigos | January 23, 2023
A summary of the prostate and bladder cancer session of the Conversations & Trending Topics in GU Cancers conference.
The UromigosThe Uromigos | January 9, 2023
Sam Chang, MD, MBA, joins The Uromigos to discuss the results of IL-15RαFc superagonist N-803 for papillary NMIBC.
The UromigosThe Uromigos | December 20, 2022
Is cisplatin any different from carboplatin in advanced bladder cancer? The Uromigos debate the topic with Matt Galsky, MD.
The UromigosThe Uromigos | November 28, 2022
Dr. Andrea Necchi describes his recent phase 2 study on the use of neoadjuvant pembrolizumab and nab-paclitaxel for MIBC.
The UromigosThe Uromigos | October 25, 2022
The Uromigos chat with Cora Sternberg on her paper on FGFR inhibition in advanced urothelial cancer.
Advertisement
Advertisement